Finance

Lists
Why is VTVT down 7,32%?
Dive Deeper
VTVT:NASDAQ
vTv Therapeutics Inc
28,23 USD
-7,32%
(-2,23) 1D
13-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTVT...
Open
30,75 USD
High
31,22 USD
Low
27,87 USD
Mkt. cap
111,62 млн
Avg. vol.
37,90 миң
Volume
41,66 миң
52-wk high
44,00 USD
52-wk low
19,80 USD
EPS
-1,06 USD
Beta
0,23
Shares outstanding
3,95 млн
No. of employees
26
Open
30,75 USD
High
31,22 USD
Low
27,87 USD
Mkt. cap
111,62 млн
Avg. vol.
37,90 миң
Volume
41,66 миң
52-wk high
44,00 USD
52-wk low
19,80 USD
EPS
-1,06 USD
Beta
0,23
Shares outstanding
3,95 млн
No. of employees
26
News stories
From web sources and news partners
About vTv Therapeutics Inc
CEO-
Employees26
Founded2015
HeadquartersХай Пойнт, Север Каролина, Америка Кошмо Штаттары
Sector-
Websitevtvtherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to VTVT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for VTVT in the last 3 months.
Highest
Current 28,23 USD
67,00 USD (+137,34%)
Average
56,80 USD (+101,20%)
Lowest
42,00 USD (+48,78%)
Analyst
Recommendation
Action
Price target
Projected
Date
Adam Walsh
Roth MKM
Buy
Reiterated
58,00 USD
+105,5%
10/06/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
60,00 USD
+112,5%
10/05/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
42,00 USD
+48,8%
09/21/2026
Kambiz Yazdi
BTIG
Buy
Maintained
57,00 USD
+101,9%
08/06/2026
Ritu Baral
TD Cowen
Buy
Maintained
67,00 USD
+137,3%
08/07/2026
Michael King
Rodman & Renshaw
Buy
Initiated
67,00 USD
+137,3%
06/30/2026
James Molloy
Alliance Global Partners
Buy
Reiterated
55,00 USD
+94,8%
05/14/2026
Michael DiFiore
Evercore ISI
Buy
Initiated
44,00 USD
+55,9%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
36,84 млн
-
Cost of goods sold
7,02 млн
3,91 млн
8,98 млн
8,77 млн
Cost of revenue
7,02 млн
3,91 млн
8,98 млн
8,77 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,68 млн
3,98 млн
4,60 млн
5,16 млн
Operating expense
3,68 млн
3,98 млн
4,60 млн
5,16 млн
Total operating expenses
10,70 млн
7,88 млн
13,58 млн
13,93 млн
Operating income
-10,70 млн
-7,88 млн
23,26 млн
-13,93 млн
Other non operating income
-40,00 миң
-117,00 миң
33,00 миң
64,00 миң
EBT including unusual items
-10,34 млн
-7,14 млн
24,13 млн
-13,05 млн
EBT excluding unusual items
-10,34 млн
-7,14 млн
24,13 млн
-13,05 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8,70 млн
-7,14 млн
24,13 млн
-13,05 млн
Net profit margin
-
-
65,51%
-
Earnings per share
-1,08
-0,58
1,65
-1,05
Interest and investment income
399,00 миң
865,00 миң
838,00 миң
812,00 миң
Interest expense
-5,00 миң
-1,00 миң
-
-
Net interest expenses
394,00 миң
864,00 миң
838,00 миң
812,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,70 млн
-7,88 млн
23,26 млн
-13,93 млн
Gain or loss from assets sale
-
6,00 миң
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору